Clinical Trials
124 trialsNCT05319730 2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT05379595 2026-05-08
OrigAMI-1
Janssen Research & Development, LLC
Phase 1/2 Recruiting
NCT05083481 2026-05-05
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Astellas Pharma Inc
Phase 1/2 Active not recruiting
NCT06620302 2026-05-05
Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma
Children's Oncology Group
Phase 1/2 Recruiting
NCT07214298 2026-04-30
Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Roswell Park Cancer Institute
Phase 1/2 Recruiting
NCT06483555 2026-04-23
PANGEA
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT04796012 2026-04-16
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
University of Texas Southwestern Medical Center
Phase 1/2 Recruiting
NCT06541262 2026-04-09
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Milton S. Hershey Medical Center
Phase 1/2 Recruiting
NCT04657068 2026-03-18
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Artios Pharma Ltd
Phase 1/2 Recruiting
NCT05384821 2026-03-18
MetroWilms
Centre Oscar Lambret
Phase 1/2 Recruiting
NCT05004116 2026-03-04
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT05846867 2026-03-04
A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer
Akeso
Phase 1/2 Active not recruiting
NCT04238819 2026-03-02
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Phase 1/2 Completed
NCT07391566 2026-02-06
LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation
Luye Pharma Group Ltd.
Phase 1/2 Not yet recruiting
NCT00989469 2026-02-05
NEXIRI
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 1/2 Completed
NCT05027386 2026-02-05
Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study.
Sun Yat-sen University
Phase 1/2 Recruiting
NCT06771622 2026-02-04
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
FBD Biologics Limited
Phase 1/2 Active not recruiting
NCT06208657 2026-01-28
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
Australian & New Zealand Children's Haematology/Oncology Group
Phase 1/2 Recruiting
NCT07364422 2026-01-23
To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer
Onconic Therapeutics Inc.
Phase 1/2 Not yet recruiting
NCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT07346157 2026-01-16
PNOC044
University of California, San Francisco
Phase 1/2 Not yet recruiting
NCT07056777 2026-01-13
Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer
Zhejiang Doer Biologics Co., Ltd.
Phase 1/2 Recruiting
NCT04689347 2026-01-12
5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 1/2 Recruiting
NCT07334301 2026-01-12
BEACON2
University of Birmingham
Phase 1/2 Recruiting
NCT07155200 2025-12-22
Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)
Washington University School of Medicine
Phase 1/2 Recruiting
NCT04067115 2025-12-17
U01CA236220
Sarcoma Alliance for Research through Collaboration
Phase 1/2 Completed
NCT05342636 2025-12-17
A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT04821284 2025-11-04
Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer
Thomas Jefferson University
Phase 1/2 Active not recruiting
NCT03184870 2025-10-09
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT07204574 2025-10-02
The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer
Chang Gung Memorial Hospital
Phase 1/2 Recruiting
NCT05381038 2025-09-23
Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI
National University Hospital, Singapore
Phase 1/2 Recruiting
NCT02611024 2025-07-09
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
Phase 1/2 Completed
NCT04581473 2025-06-05
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
CARsgen Therapeutics Co., Ltd.
Phase 1/2 Active not recruiting
NCT04211675 2025-05-13
STING
Nationwide Children's Hospital
Phase 1/2 Recruiting
NCT01550510 2025-05-06
Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA
Thomas Jefferson University
Phase 1/2 Terminated
NCT03428958 2025-04-23
A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
NuCana plc
Phase 1/2 Completed
NCT00545545 2025-03-19
Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma
HiberCell, Inc.
Phase 1/2 Completed
NCT05319639 2025-02-27
Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab
Fujian Cancer Hospital
Phase 1/2 Recruiting
NCT04095221 2025-02-20
A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT05278728 2025-02-07
Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer
Biotech Pharmaceutical Co., Ltd.
Phase 1/2 Completed
NCT04492033 2025-01-27
A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients
Handok Inc.
Phase 1/2 Terminated
NCT03699319 2025-01-23
CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT03368963 2025-01-07
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
Emory University
Phase 1/2 Active not recruiting
NCT03535727 2024-12-31
A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT06139211 2024-12-20
A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Recruiting
NCT03009058 2024-11-25
MODULATE
Immodulon Therapeutics Ltd
Phase 1/2 Terminated
NCT03879798 2024-10-10
DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Terminated
NCT05824455 2024-09-05
A Clinical Study of IMP4297 Capsule (JS109) Combined With Irinotecan in the Treatment of Advanced Malignant Solid Tumors
Shanghai Jun Pai Ying Shi Therapeutics Co., Ltd.
Phase 1/2 Terminated
NCT03263429 2024-08-30
Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer
Vanderbilt-Ingram Cancer Center
Phase 1/2 Completed
NCT01505608 2024-08-06
Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma
Milton S. Hershey Medical Center
Phase 1/2 Terminated